Please ensure Javascript is enabled for purposes of website accessibility

Roche Tests Arthritis Drug Actemra for COVID-19 Pneumonia

By Brian Orelli, PhD - Mar 23, 2020 at 7:29PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The anti-inflammatory drug could help patients infected with the novel coronavirus.

Through its Genentech unit, Roche (RHHBY 0.44%) is testing its rheumatoid arthritis drug Actemra as a potential treatment for pneumonia in patients with COVID-19, the disease caused by the new coronavirus. Roche said the Food and Drug Administration approved the start of the company's COVACTA phase 3 clinical trial.

The idea of using a rheumatoid arthritis drug for COVID-19 isn't that far-fetched. Some doctors have already tested Actemra on COVID-19 patients with some success, although the studies didn't have a control group. And last week, Regeneron (REGN -0.85%) and Sanofi (SNY 1.79%) started a clinical trial of their interleukin-6 inhibitor Kevzara, which is also approved for rheumatoid arthritis.

Actemra works by blocking the interleukin-6 receptor, which reduces the inflammatory response in rheumatoid arthritis patients. Roche thinks it could help patients with COVID-19 because patients fighting off the infection can go through what's called a cytokine storm, wherein the immune system's positive feedback loop goes haywire and causes the immune system to ramp up higher and higher until it's attacking the patient's own cells. Interleukin-6 is one of those cytokines involved in the positive feedback loop.

Restricted area with patient and doctors

Image source: Getty Images.

The clinical trial, which will be run in collaboration with the U.S. government's Biomedical Advanced Research and Development Authority, will compare Actemra plus standard of care (SOC) to placebo plus SOC. The study will measure clinical status, mortality, mechanical ventilation, and intensive care unit variables over 60 days. Roche plans to conduct an interim analysis to get an early look at whether the drug has efficacy in COVID-19 patients.

Roche also announced that it plans to provide 10,000 vials of Actemra to the U.S. strategic national stockpile. The company thinks there's enough of the drug in the supply chain that the stockpiling won't affect the use in rheumatoid arthritis.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Roche Holding AG Stock Quote
Roche Holding AG
RHHBY
$40.92 (0.44%) $0.18
Sanofi Stock Quote
Sanofi
SNY
$54.01 (1.79%) $0.95
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$651.57 (-0.85%) $-5.58

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
331%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.